---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028595"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:07:18.308675+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q2 2022 net loss $27.4M; cash $246.3M; IND accepted for CDK4/6 inhibitor PRT3645

## Summary
- Net loss $27.4M ($0.58/share) vs $26.9M ($0.58/share) Q2 2021; R&D declined $1.1M to $21.3M.
- Cash, equivalents, and marketable securities $246.3M as of June 30, 2022; funds operations into H2 2024.
- FDA accepted IND for brain-penetrant CDK4/6 inhibitor PRT3645; Phase 1 to begin Q4 2022 in multiple cancers.
- PRMT5 (PRT811) expansion cohort data readout and next steps expected H2 2022; MCL1 combo data by end of 2022.
- SMARCA2/BRM degrader program on track to file IND by year-end 2022.

## SEC filing metadata
- accession: 0001564590-22-028595
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000156459022028595/0001564590-22-028595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000156459022028595/prld-8k_20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028595
- JSON: https://secwatch.observer/filing/0001564590-22-028595.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.